MYGN Myriad Genetics Inc

Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, president and CEO of Myriad Genetics, is scheduled to present at the J.P. Morgan 33rd Annual Healthcare Conference at 9:30 a.m. Pacific on January 12, 2015, at the Westin St. Francis in San Francisco, California.

The presentation will be available to interested parties through a live audio webcast accessible through a link in the investor information section of Myriad's website at www.myriad.com.

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad is focused on strategic directives to grow existing markets, diversify through the introduction of new products, including companion diagnostics, as well as to expand internationally. For more information on how Myriad is making a difference, please visit the Company's websites: www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan Lung Cancer, BRACAnalysis CDx, HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G

CONTACT: Media Contact:
         Ron Rogers
         (801) 584-3065
         rrogers@myriad.com
         
         Investor Contact:
         Scott Gleason
         (801) 584-1143
         sgleason@myriad.com